Methods for reprogramming somatic cells
The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
1. A somatic cell comprising an exogenous nucleic acid encoding Oct4 and an amount of Oct4 expression comparable to the amount of Oct4 expression in an embryonic stem cell.
2. A somatic cell comprising an exogenous nucleic acid encoding Oct4 and an amount of Oct4 protein sufficient to make the cell more susceptible to reprogramming.
3. The somatic cell of any one of claims 1 to 2 , wherein the somatic cell is a mammalian cell.
4. The somatic cell of any one of claims 1 to 2 , wherein the somatic cell is a human cell or a mouse cell.
5. The somatic cell of any one of claims 1 to 2 , wherein the cell is an adult stem cell.
6. The somatic cell of claim 5 , wherein the adult stem cell is selected from the group consisting of: a hematopoietic stem cell, a neural stem cell, and a mesenchymal stem cell.
7. A composition comprising an isolated cDNA encoding an Oct4 protein operably linked to at least one regulatory sequence and DNA methylation inhibitor, a histone deacetylase inhibitor, or PD09859.
8. A composition comprising an isolated cDNA encoding an Oct4 protein operably linked to at least one regulatory sequence, an isolated cDNA encoding a Sox2 protein operably linked to at least one regulatory sequence, and an isolated adult stem cell.
9. A composition comprising an isolated cDNA encoding an Oct4 protein operably linked to at least one regulatory sequence, an isolated cDNA encoding a Nanog protein operably linked to at least one regulatory sequence, and an isolated adult stem cell.
10. The composition of any one of claims 8 and 9 , wherein the adult stem cell is a human adult stem cell or a mouse adult stem cell.
11. The composition of any one of claims 8 and 9 , wherein the composition further comprises a DNA methylation inhibitor, a histone deacetylase inhibitor, or PD09859.